**Supplementary Material:**

**Hybrid Silica-Coated PLGA Nanoparticles for Enhanced Enzyme-Based Therapeutics**

Kyle T. Gustafson1,2\*, Negin Mokhtari1,3\*, Elise C. Manalo1, Jose Montoya Mira1,2, Austin Gower1, Ya-San Yeh1,4, Mukanth Vaidyanathan1,5, Sadik C. Esener1-3,5, Jared M. Fischer1,6\*\*

1Cancer Early Detection Advanced Research (CEDAR) Center, Knight Cancer Institute, Oregon Health & Science University (OHSU)

2Department of Biomedical Engineering, School of Medicine, Oregon Health & Science University

3Department of Electrical Engineering, Jacobs School of Engineering, University of California, San Diego (UCSD)  
4Department of Bioengineering, Jacobs School of Engineering, University of California, San Diego

5Department of NanoEngineering, Jacobs School of Engineering, University of California, San Diego

6Department of Molecular and Medical Genetics, School of Medicine, Oregon Health & Science University

\*Authors contributed equally

\*\*Corresponding author: [fischerj@ohsu.edu](mailto:fischerj@ohsu.edu)

This section contains two supporting tables. **Supporting Table 1** highlights active enzymes that are used to treat a variety of diseases. **Supporting Table 2** lists commercial drug formulations that utilize PLGA particles as delivery vehicles.

|  |  |  |  |
| --- | --- | --- | --- |
| **Active enzyme** | **Enzyme formulation(s)** | **FDA Status** | **Disease(s)** |
| asparaginase | colaspase; crisantaspase; pegaspargase; calaspargase pegol-mknl | approved | acute lymphoblastic leukemia; lymphoblastic lymphoma |
| phenylalanine ammonia lyase | pegvaliase | approved | phenylketonuria |
| arginine deiminase | pegargiminase; ADI-PEG 20 | phase 2 | metastatic melanoma; hepatocellular carcinoma; mesothelioma |
| arginase | pegzilarginase | phase 3; phase 1 | Arginase 1 deficiency; melanoma, leukemia, lymphoma |
| methioninase |  | phase 1 | lung carcinoma, breast cancer, renal cancer, lymphoma |
| kynureninase | PEG-KYNase | preclinical research | melanoma, breast carcinoma, colon carcinoma |
| cysteinase |  | preclinical research | prostate cancer, breast cancer |

**Supporting Table 1: Active enzymes used to treat diseases**

**Supporting Table 2: Commercial formulations using PLGA particles for drug delivery**

|  |  |  |
| --- | --- | --- |
| **Commercial name(s)** | **Active ingredient** | **Disease(s)** |
| Decapeptyl®; Decapeptyl™ SR | triptorelin | prostate cancer, endometriosis |
| Bydureon®; Bydureon Bcise® | exenatide | type 2 diabetes |
| Sandostatin LAR®; Sandostatin LAR® Depot | octreotide | acromegaly |
| Suprecur® MP | buserelin | prostate cancer, endometriosis |
| Somatuline® LA | lanreotide | acromegaly |
| Trelstar™ Depot | triptorelin | prostate cancer |
| Lupron Depot® | leuprolide | prostate cancer |
| Nutropin Depot® | somatropin | pediatric growth hormone deficiency |